+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 0 - 365Days
All Genders
ID06317662

Study of Blinatumomab with Chemotherapy and Randomized Addition of Venetoclax for Infants with Newly Diagnosed KMT2A-Rearranged or Non-Rearranged Acute Lymphoblastic Leukemia

Led by National Cancer Institute (NCI) · Updated on 2026-10-27

153

Participants Needed

117

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the addition of venetoclax andor blinatumomab to standard chemotherapy in infants with newly diagnosed acute lymphoblastic leukemia ALL, specifically those with KMT2A gene rearrangements KMT2A-R or without KMT2A-G. This phase II study aims to assess the safety, tolerability, and effectiveness of these combined treatments compared to usual chemotherapy alone. The trial also explores multiple outcomes such as remission rates, event-free survival, pharmacokinetics, and immune effects in this vulnerable infant population. Treatment involves an initial steroid prephase followed by induction therapy where infants with KMT2A-R ALL are randomized to either standard chemotherapy alone or combined with venetoclax, while KMT2A-G patients receive chemotherapy with blinatumomab. Treatment cycles include induction, blinatumomab blocks, consolidation, MARMA, delayed intensification, and maintenance phases. Various drugs are administered by different routes including oral, intravenous, intrathecal, and intramuscular, with detailed schedules for each treatment component. The study also includes a closed safety phase cohort and multiple cohorts within the expansion phase to evaluate different dosing regimens. Participants undergo numerous assessments such as bone marrow aspirations, blood sample collections, echocardiography or MUGA scans, and possibly CT, MRI, FDG-PET, or lumbar puncture if clinically needed. Researchers monitor minimal residual disease, dose-limiting toxicities, pharmacokinetics of study drugs, and long-term outcomes including event-free survival over up to three years of follow-up after treatment completion. The total participation time may extend through the treatment period plus follow-up, encompassing detailed monitoring and safety evaluations throughout.

CONDITIONS

Brief Title

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here